JP2020503246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503246A5 JP2020503246A5 JP2019518480A JP2019518480A JP2020503246A5 JP 2020503246 A5 JP2020503246 A5 JP 2020503246A5 JP 2019518480 A JP2019518480 A JP 2019518480A JP 2019518480 A JP2019518480 A JP 2019518480A JP 2020503246 A5 JP2020503246 A5 JP 2020503246A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition
- substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010029412 Nightmare Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010040981 Sleep attacks Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- -1 nitro, hydroxy Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404917P | 2016-10-06 | 2016-10-06 | |
| PCT/US2017/055598 WO2018067971A1 (en) | 2016-10-06 | 2017-10-06 | Carbamoyl phenylalaninol compounds and uses therof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503246A JP2020503246A (ja) | 2020-01-30 |
| JP2020503246A5 true JP2020503246A5 (enExample) | 2020-10-22 |
| JP7074750B2 JP7074750B2 (ja) | 2022-05-24 |
Family
ID=60183122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518480A Active JP7074750B2 (ja) | 2016-10-06 | 2017-10-06 | カルバモイルフェニルアラニノール化合物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10710958B2 (enExample) |
| EP (2) | EP4316592A3 (enExample) |
| JP (1) | JP7074750B2 (enExample) |
| KR (1) | KR102616545B1 (enExample) |
| CN (1) | CN110049966A (enExample) |
| CA (1) | CA3039045A1 (enExample) |
| ES (1) | ES2964943T3 (enExample) |
| MY (1) | MY202185A (enExample) |
| PH (1) | PH12019500751A1 (enExample) |
| SG (1) | SG11201903076QA (enExample) |
| WO (1) | WO2018067971A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| KR102643275B1 (ko) | 2017-07-31 | 2024-03-04 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 카바모일 페닐알라니놀 유사체 및 이의 용도 |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| CA2587481A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Phenylalkylamino carbamates adjunctive therapy for depression |
| ES2435403T3 (es) | 2005-06-08 | 2013-12-19 | Sk Biopharmaceuticals Co., Ltd. | Tratamiento de trastornos del sueño y vigilia |
| ES2344469T3 (es) | 2005-06-22 | 2010-08-27 | Sk Holdings Co., Ltd. | Tratamiento de disfuncion sexual. |
| KR102173587B1 (ko) | 2009-06-22 | 2020-11-04 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US9359290B2 (en) | 2013-03-13 | 2016-06-07 | Jazz Pharmaceuticals International Iii Limited | Treatment of cataplexy |
| CN110638805A (zh) | 2013-07-12 | 2020-01-03 | 爵士制药国际Iii有限公司 | 促进吸烟停止 |
| KR102309836B1 (ko) | 2013-07-18 | 2021-10-12 | 에스케이바이오팜 주식회사 | 비만의 치료 |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
-
2017
- 2017-10-06 EP EP23199791.7A patent/EP4316592A3/en active Pending
- 2017-10-06 CN CN201780075629.4A patent/CN110049966A/zh active Pending
- 2017-10-06 ES ES17790906T patent/ES2964943T3/es active Active
- 2017-10-06 CA CA3039045A patent/CA3039045A1/en not_active Abandoned
- 2017-10-06 MY MYPI2019001915A patent/MY202185A/en unknown
- 2017-10-06 JP JP2019518480A patent/JP7074750B2/ja active Active
- 2017-10-06 SG SG11201903076QA patent/SG11201903076QA/en unknown
- 2017-10-06 KR KR1020197013113A patent/KR102616545B1/ko active Active
- 2017-10-06 WO PCT/US2017/055598 patent/WO2018067971A1/en not_active Ceased
- 2017-10-06 EP EP17790906.6A patent/EP3523275B1/en active Active
- 2017-10-06 US US16/338,925 patent/US10710958B2/en active Active
-
2019
- 2019-04-05 PH PH12019500751A patent/PH12019500751A1/en unknown
-
2020
- 2020-06-03 US US16/891,464 patent/US11149000B2/en active Active
-
2021
- 2021-09-09 US US17/470,063 patent/US11780805B2/en active Active
-
2023
- 2023-09-18 US US18/469,032 patent/US20240018098A1/en not_active Abandoned
-
2024
- 2024-11-05 US US18/937,105 patent/US20250059136A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503246A5 (enExample) | ||
| JP2020530837A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| JP2014526435A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2015505296A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2017503000A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| RU2020108634A (ru) | Аналоги карбамоилфенилаланинола и способы их применения | |
| JP2015532296A5 (enExample) | ||
| JP2005521671A5 (enExample) | ||
| JP2015531764A5 (enExample) | ||
| JP2012097115A5 (enExample) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2015500223A5 (enExample) | ||
| JP2016539157A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2013507371A5 (enExample) |